NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. (NBSE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NBSE · as of Jun 9, 2026
Key Statistics
Explore NeuBase Therapeutics, Inc. Data
nbse stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 50.0%
Competitors & Peers
nbse competitorsNBSE
ASLN
CWBR
CYTO
IMPL
NMTRQStock Performance
Full HistoryAbout NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant…
what is neubase therapeutics, inc. · nbse stock overview · neubase therapeutics, inc. company profile · who is neubase therapeutics, inc. ceo · nbse NASDAQ · neubase therapeutics, inc. headquarters · neubase therapeutics, inc. business segments
About Stock Overview & Key Data
NeuBase Therapeutics, Inc. (NBSE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 28, 2004. As of the latest trading session, NBSE stock price is $0.38, with a market capitalization of $1.4M. The stock has returned -89.84% over the past 12 months and -45.62% year-to-date.
According to 6 Wall Street analysts, the consensus rating for NeuBase Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2022, NeuBase Therapeutics, Inc. reported revenue of — and net income of -$34.2M. For detailed data — including NeuBase Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, NeuBase Therapeutics, Inc. (NBSE) stock price is $0.38. The stock is traded on NASDAQ under the ticker symbol NBSE. The 52-week range is $0.36 – $4.44.